Forman S J, O'Donnell M R, Nademanee A P, Snyder D S, Bierman P J, Schmidt G M, Fahey J L, Stein A S, Parker P M, Blume K G
Blood. 1987 Aug;70(2):587-8.
We report the treatment outcome of allogeneic bone marrow transplantation in ten patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Six patients are alive and well for 6 to 30 months (median 19 months) after transplantation. Four patients died with transplant related complications. In view of the poor prognosis associated with this disease, marrow ablation followed by allogeneic or syngeneic marrow grafting may be the preferred treatment modality if a suitable marrow donor is available.
我们报告了10例费城染色体阳性急性淋巴细胞白血病患者接受异基因骨髓移植的治疗结果。6例患者在移植后6至30个月(中位时间19个月)存活且状况良好。4例患者死于移植相关并发症。鉴于该疾病预后较差,如果有合适的骨髓供者,骨髓清除后进行异基因或同基因骨髓移植可能是首选的治疗方式。